Nanatinostat
- Generic Name
- Nanatinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19FN6O2
- CAS Number
- 1256448-47-1
- Unique Ingredient Identifier
- YTL7A418KQ
- Background
Nanatinostat is under investigation in clinical trial NCT00697879 (Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours).
- Associated Conditions
- -
- Associated Therapies
- -
A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers
- Conditions
- Advanced Cancer
- Interventions
- Drug: Nanatinostat mesylate tablets in combination with ValganciclovirDrug: Single-agent Nanatinostat (free base) tabletsDrug: [14C]-NanatinostatDrug: Nanatinostat (free base) tablets in combination with Valganciclovir
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Viracta Therapeutics, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT06302140
- Locations
- ๐ช๐ธ
START Madrid - CIOCC - Hospital Universitario HM Sanchinarro, Madrid, Spain
Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC
- Conditions
- Nasopharyngeal CarcinomaEBV-Related Gastric CarcinomaEBV-Related LeiomyosarcomaEBV Related CarcinomaEBV-Related Sarcoma
- Interventions
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Viracta Therapeutics, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05166577
- Locations
- ๐บ๐ธ
Stanford Cancer Center, Stanford, California, United States
๐บ๐ธUniversity of Colorado Hospital, Aurora, Colorado, United States
๐บ๐ธUniversity of Texas MD Anderson Cancer Center, Houston, Texas, United States
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
- Conditions
- EBV Related Non-Hodgkin's LymphomaEBV-Positive DLBCL, NOSEBV Related PTCL, NOSEpstein-Barr Virus Associated Lymphoproliferative DisorderEBV-Related PTLDEBV Associated Lymphoma
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Viracta Therapeutics, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT05011058
- Locations
- ๐บ๐ธ
The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
๐บ๐ธCity of Hope, Duarte, California, United States
๐บ๐ธDavid Geffen School of Medicine - UCLA, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.